Alumis Inc. (ALMS) vs Gyre Therapeutics, Inc. (GYRE)
A side-by-side comparison of Alumis Inc. and Gyre Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALMS
Alumis Inc.
$6.84HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
GYRE
Gyre Therapeutics, Inc.
$7.35HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ALMS vs GYRE
growth of $100 · dividends reinvested · last 2yALMS -48.6% (-28.3%/yr)GYRE -31.1% (-17.0%/yr)GYRE compounded faster over this window
ALMS GYRE
ALMS vs GYRE: by the numbers
- •ALMS is the larger company ($844M vs $819M market cap).
- •Both run net losses; GYRE's is the smaller (-14.52% vs -5933.45% net margin).
Metrics side by side
Valuation
| Metric | ALMS | GYRE |
|---|---|---|
| P/S ratio | 114.12 | 6.86 |
| P/B ratio | 1.87 | 7.59 |
Profitability
| Metric | ALMS | GYRE |
|---|---|---|
| Gross margin | 88.23% | 94.30% |
| Operating margin | -1776.32% | 9.86% |
| Net margin | -5933.45% | -14.52% |
| ROE | -97.08% | -13.30% |
| ROIC | -94.76% | -9.77% |
Growth (annualized)
| Metric | ALMS | GYRE |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 84.92% |
| Total return CAGR (5Y) | N/A | -0.34% |
Go deeper
Dig into the metrics
Alumis ROEGyre Therapeutics ROEAlumis operating marginGyre Therapeutics operating marginAlumis revenue growthGyre Therapeutics revenue growthAlumis free cash flowGyre Therapeutics free cash flow
Alumis & Gyre Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.